Kacprzyk F, Chrzanowski W
Kliniki Nefrologicznej Instytutu Chorób Wewnetrznych Akademii Medycznej, Lodzi.
Pol Arch Med Wewn. 1996 Sep;96(3):215-23.
The circulating immune complexes (CIC), urinary immune complexes (UIC), C3 and C4 in urine (UC3 and UC4) in 99 patients with immunologic glomerular diseases: 13 with extracapillaris GN (ExGN), 38 with membranoproliferative GN (MPGN), 33 with mesangial proliferative GN (MesPGN), 5 with focal segmental glomerulosclerosis (FSGS), 5 with membranous nephropathy (MN), and 3 with minimal change nephropathy (MC) were investigated in the study. Depending on the (IS) immunosuppressive treatment all patients were classified into 3 groups. Group I: 61 recently biopsied patients with glomerular disease consisted of patients attending our renal department, group II: 24 patients with biopsy proven glomerular disease IS treated in the past but with GN with restrained disease activity, group III: 14 patients with active glomerulopathy who have been treated for some months. Nephelometry C1q binding test was used for CIC detection and 3.5% polyethylene glycol precipitate for its detection in urine by C1q binding test was applied. Radial immunodiffusion (NANORID) method was used for urine C3 and C4 detection. UC3 were detected in urine from 37% of all patients: in 39% patients of group I (GN at time of diagnosis), 38% of group II (GN with restrained disease activity) and 36% of group III (active GN received immunosuppressive therapy for several months). It suggest that nonimmunological-mechanism induce C3 detected in the rine of such patients. According to histological findings UC3 was detected in 3 patients with ExGN of group I, in patient with ExGN of group II and in about half patients with MPGN from group I and II, in about 25% patients with MesPGN from group I and II. About half patients with MesPGN of group III, one patient with MPGN of group III and a few patients with other histological findings of group I were UC3 positive. Simultaneous excretion of C4 in urine was detected in some UC3 positive patients (in about 5% patients). At the same time in about 50% UC3 positive patients was observed urinary excretion of IC. CIC and UIC were detected in 25% of all patients: in 29% of group I, in 17% of group II, and in 29% patients of group III. According to histological findings CIC was detected in 3 patients with ExGN, in 7 patients with MPGN from 26 of group I, and 3 from 7 with MPGN of group II, and 3 patients with MesPGN of group I and 1 patients with MesPGN of group II, and 33% patients with MesPGN of group III with high proteinuria. These findings suggested that urinary IC reflected the immunological activity of glomerulopathy and their presence in patients urine after IS treatment suggests incomplete response to this therapy while urinary C3 and C4 were connected with urinary protein excretion and may be of importance in tubulointerstitial injury and progression of renal insufficiency.
本研究对99例免疫性肾小球疾病患者的循环免疫复合物(CIC)、尿免疫复合物(UIC)、尿C3和C4(UC3和UC4)进行了检测,其中13例为毛细血管外增生性肾小球肾炎(ExGN),38例为膜增生性肾小球肾炎(MPGN),33例为系膜增生性肾小球肾炎(MesPGN),5例为局灶节段性肾小球硬化(FSGS),5例为膜性肾病(MN),3例为微小病变肾病(MC)。根据免疫抑制治疗(IS)情况,将所有患者分为3组。第一组:61例近期经肾活检确诊的肾小球疾病患者,均为我院肾内科门诊患者;第二组:24例曾接受过活检证实的肾小球疾病IS治疗且疾病活动得到控制的患者;第三组:14例接受了数月治疗的活动性肾小球病患者。采用比浊法C1q结合试验检测CIC,应用3.5%聚乙二醇沉淀法通过C1q结合试验检测尿中的CIC。采用放射免疫扩散法(NANORID)检测尿C3和C4。37%的患者尿中检测到UC3:第一组(诊断时为肾小球疾病)的患者中39%检测到,第二组(疾病活动得到控制的肾小球疾病)的患者中38%检测到,第三组(接受了数月免疫抑制治疗的活动性肾小球病)的患者中36%检测到。这表明非免疫机制导致了此类患者尿中C3的检测。根据组织学检查结果,第一组中3例ExGN患者、第二组中1例ExGN患者以及第一组和第二组中约半数MPGN患者、第一组和第二组中约25%的MesPGN患者尿中检测到UC3。第三组中约半数MesPGN患者、第三组中1例MPGN患者以及第一组中少数其他组织学类型的患者尿中UC3呈阳性。部分UC3阳性患者(约5%)尿中同时检测到C4排泄。同时,约50%的UC3阳性患者尿中观察到免疫复合物排泄。25%的患者检测到CIC和UIC:第一组中29%检测到,第二组中17%检测到,第三组中29%检测到。根据组织学检查结果,3例ExGN患者、第一组26例MPGN患者中的7例、第二组7例MPGN患者中的3例、第一组3例MesPGN患者、第二组1例MesPGN患者以及第三组中33%蛋白尿水平高的MesPGN患者检测到CIC。这些结果表明,尿免疫复合物反映了肾小球病的免疫活性,IS治疗后患者尿中存在免疫复合物提示对该治疗反应不完全,而尿C3和C4与尿蛋白排泄相关,可能在肾小管间质损伤和肾功能不全进展中起重要作用。